Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783100 | 0.88 | SETD7 (0.44) | DNM1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL10201764 | 0.84 | DNM1 (0.49) | DNM1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL3232022 | 0.84 | DNM1 (0.42) | DNM1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL23922070 | 0.82 | DNM1 (0.47) | DNM1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL14052421 | 0.82 | PTGS1 (0.47) | ALDH1A1POLBCA14MEN1KMT2A | |
| SCHEMBL10734749 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDPAOXCA14 | |
| SCHEMBL21222710 | 0.81 | DNM1 (0.46) | DNM1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL280234 | 0.80 | TDP1 (0.52) | KDM4EALDH1A1HPGDPOLBCA14 | |
| SCHEMBL10879405 | 0.79 | DNM1 (0.45) | DNM1KDM4EALDH1A1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL22729366 | 0.79 | DNM1 (0.45) | DNM1KDM4EALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210316001-A1 | AMINO-REACTIVE POSITIVELY CHARGED ATRP INITIATORS THAT MAINTAIN THEIR POSITIVE CHARGE DURING SYNTHESIS OF BIOMACRO-INITIATORS | CARNEGIE MELLON UNIVERSITY | 2021-10-14 | — | — | US | disclosed |
| US-7902368-B2 | Cationic substituted 2,2,6,6-tetraalkylpiperidinyl alkoxyamines | BASF SE (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306382-A1 | CATIONIC ALKOXYAMINES | MUEHLEBACH ANDREAS | 2009-12-10 | — | — | US | disclosed |
| EP-1515950-B1 | CATIONIC ALKOXYAMINES AND THEIR USE IN PRODUCING NANO PARTICLES FROM NATURAL OR SYNTHETIC CLAYS | BASF SE (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-7595359-B2 | Organoclays; coatings, sealants, caulks, adhesives and plastic additives | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20050215691-A1 | Cationic alkoxyamines and their use in producing nano particles from natural or synthetic clays | BASF SE (DE) | 2005-09-29 | — | — | US | disclosed |
| CN-1662499-A | Cationic alkoxyamines and their use in the preparation of nanoparticles from natural or synthetic clays | CIBA SC HOLDING AG (CH) | 2005-08-31 | — | — | CN | disclosed |
| EP-1515950-A1 | CATIONIC ALKOXYAMINES AND THEIR USE IN PRODUCING NANO PARTICLES FROM NATURAL OR SYNTHETIC CLAYS | Ciba SC Holding AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004000809-A1 | CATIONIC ALKOXYAMINES AND THEIR USE IN PRODUCING NANO PARTICLES FROM NATURAL OR SYNTHETIC CLAYS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306382-A1 | CATIONIC ALKOXYAMINES | ALKBH2, ALKBH3, ALKBH5 | DNM1 2754/4885KDM4E 284/4885ALDH1A1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.